Q2 FY2026 · ended Jun 30, 2026 · Revenue $37.67M, +1.3% YoY · Filed Aug 10, 2026
Heron Therapeutics, Inc. /DE/ (HRTX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $37.7 million and a net loss of $5.5 million. Free cash flow was -$2.4 million. As of Jun 30, 2026 it held $42.7 million in cash and investments and $5.7 million in total debt.
Revenue
$37.67M
+1.3% vs year-ago quarter
Net income
$-5.49M
-130.5% vs year-ago quarter
Operating cash flow
$-2.21M
+79.6% vs year-ago quarter
Free cash flow
$-2.35M
+78.8% vs year-ago quarter
EPS
$-0.03
-50.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
189.85M
+23.9% vs year-ago quarter
Net cash
$36.96M
Q2 FY2026
Operating margin
-7.2%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 818033
- Former names
- AP PHARMA INC /DE/ (until Jan 7, 2014); ADVANCED POLYMER SYSTEMS INC /DE/ (until Apr 6, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $37.7M | $34.7M | $40.6M | $38.2M | $37.2M |
| Operating income | -$2.0M | -$4.8M | $38,000 | -$4.1M | -$1.6M |
| Net income | -$5.5M | -$8.1M | -$3.0M | -$17.5M | -$2.4M |
| Diluted EPS | -$0.03 | -$0.04 | -$0.02 | -$0.10 | -$0.02 |
| Operating cash flow | -$2.2M | -$1.5M | -$9.2M | $1.3M | -$10.9M |
| Free cash flow | -$2.4M | -$1.9M | -$9.2M | $1.3M | -$11.1M |
| Total assets | $252.3M | $246.2M | $255.9M | $248.9M | $232.1M |
| Total liabilities | $245.4M | $237.1M | $241.5M | $234.1M | $259.3M |
| Stockholders' equity | $6.9M | $9.1M | $14.3M | $14.9M | -$27.3M |
| Cash and investments | $42.7M | $44.8M | $46.6M | $55.5M | $40.6M |
| Total debt | $5.7M | — | $0 | $780,000 | $1.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 29, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Listing notice
|
Jun 25, 2026 | Jun 25, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 11, 2026 |
All 1000 Heron Therapeutics, Inc. /DE/ SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.